Arcion Therapeutics, Inc.: Series A $8.8M

Posted in I - Series A, Q - 1Q08, R - MID ATLANTIC, X - Diabetes, X - Pain

Arcion Therapeutics (Baltimore, MD) a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain treatment in diabetic neuropathy and post-herpetic neuralgia closed a $8.8M Series A financing. Participants include CMEA Ventures and InterWest Partners.

Feb

2008

Bridge Laboratories, Inc.: Series C $18M

Posted in I - Series C, Q - 1Q08, R - MID ATLANTIC, X - CRO

Bridge Labs (Gaithersburg, MD) a pre-clinical contract research organization closed a $18M Series C financing. Participants include Granite Global Ventures.

Jan

2007

Sequoia Pharma, Inc.: Series C $35M

Posted in I - Series C, Q - 1Q07, R - MID ATLANTIC, X - HIV

Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.

Dec

2006

VIRxSYS Corp.: Series G $20M

Posted in I - Series G, Q - 4Q06, R - MID ATLANTIC, X - HIV

VIRxSYS Corporation (Gaithersburg, MD), who is developing genetic therapies for HIV and cancer, closed a $20M Series G round of financing, the company has raised a total of $87M to date. The financing will be used to support research and clinical programs including VRX496, a gene-based immunotherapy for the treatment of HIV. Phase II clinical [...]

to top of page...